Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
Broad-Use Case Standouts balance strong reputation with reasonable volume pricing
Antibiotics : Ciprofloxacin and levofloxacin may interact with OXONEG INJECTION 1, potentially affecting its antioxidant properties and the medicine's efficacy
This Fc domain serves a dual function: it sterically hinders access to DPP-4, thereby protecting the GLP-1 moiety from enzymatic degradation, and it engages the neonatal Fc receptor (FcRn), facilitating receptor-mediated recycling and preventing lysosomal degradation following cellular uptake
These medicines are used to treat people with type 2 diabetes or to help those with obesity or overweight to lose weight
